Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
-
Perl, Alexander E. (University of Pennsylvania)
;
Larson, Richard A (University of Chicago) ;
Podoltsev, Nikolai A. (Yale School of Medicine) ;
Strickland, Stephen. (Vanderbilt-Ingram Cancer Center) ;
Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ;
Atallah, Ehab (Cancer Center-Froedtert Hospital) ;
Schiller, Gary J. (David Geffen School of Medicine at UCLA) ;
Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori,") ;
Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ;
Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Récher, Christian (Centre Hospitalier Universitaire de Toulouse) ;
Yoon, Sung Soo (Seoul National University Hospital) ;
Hosono, Naoko (University of Fukui) ;
Onozawa, Masahiro (Hokkaido University) ;
Chiba, Shigeru (University of Tsukuba) ;
Kim, Hee-Je (Catholic Hematology Hospital) ;
Hasabou, Nahla (Astellas Pharma US. Inc) ;
Lu, Qiaoyang (Astellas Pharma US. Inc) ;
Tiu, Ramon (Astellas Pharma US. Inc) ;
Levis, Mark (Johns Hopkins University) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
